Objective To determine effects of glucagon-like peptide-1 (GLP-1) receptor agonists on≥
5% or≥ 10% weight loss in overweight or obese patients with or without type 2 diabetes …

Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor
agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight …

Aims To determine the effects of glucagon-like peptide-1 receptor agonists compared with
placebo and other anti-diabetic agents on weight loss in overweight or obese patients with …

Objective Weight loss achieved with standard doses of glucagon‐like peptide‐1 (GLP‐1)
agonists among real‐world patients with type 2 diabetes has not been determined. This …

To evaluate the effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on
weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta …

Background Comparative effectiveness of 7 glucagon-like peptide 1 (GLP-1) agents on
weight loss (WL) in obesity remains unknown. Methods We performed a systematic review …

Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …

Objective To determine whether treatment with agonists of glucagon-like peptide-1 receptor
(GLP-1R) result in weight loss in overweight or obese patients with or without type 2 …

Background: Obesity can seriously damage human health and have the potential to raise
the likelihood of diabetes mellitus (DM) and other adverse outcomes. Successful therapeutic …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the
treatment of obesity. Objective To assess the weight-loss effects of GLP-1RAs in the …